K. Park

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

David Planchard, Niels Reinmuth, Jürgen R. Fischer et al. · Annals of Oncology · 2020 · 156 citations · Full text

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park et al. · Annals of Oncology · 2015 · 131 citations · Full text

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy

Bruno Coudert, Tudor–Eliade Ciuleanu, K. Park et al. · Annals of Oncology · 2011 · 102 citations · Full text

Erlotinib Maintenance Therapy, Survival Benefit, Oncology +7

A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation

SH Park, MH Lee, Hyunwoo Lee et al. · Bone Marrow Transplantation · 2002 · 93 citations

Transplantation, Hepatology, Hepatic Veno-occlusive Disease +10

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

Taofeek K. Owonikoko, H.R. Kim, Ramaswamy Govindan et al. · Annals of Oncology · 2019 · 89 citations · Full text

Medicine, Cancer Management, Pharmacology +8